|Videos|April 14, 2023
Clinical Utilization of Cemiplimab and Future Directions
Author(s)Neal Bhatia, MD, Aaron S. Farberg, MD
Experts in dermatology discuss their use cases of cemiplimab and reinforce the need for dermatologists to utilize novel and effective treatments within their patient populations.
Advertisement
Episodes in this series
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Menopause and the Skin: Recognizing Changes Beyond Aging
3
Social Media Mythbusters: Can Face Taping Really Prevent Wrinkles?
4
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
5